Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Eiko Lifesciences has informed that the Board of Directors in their meeting held today has considered and approved the following: Company (‘ELL') to enter into definitive business agreement with Vivacious Pharmatex (VPPL) for Company’s Growth and strategic positioning. Details as required under listing regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are marked as Annexure-A. The Meeting started at 10:00 AM and concluded at 11:00 AM.
The above information is a part of company’s filings submitted to BSE.